Points to consider on the non-clinical safety evaluation of anticancer drugs

1Citations
Citations of this article
11Readers
Mendeley users who have this article in their library.

Abstract

Since malignant tumors are life-threatening, the death rate from these diseases is high, and existing therapies have limited effectiveness, it is desired to provide new effective anticancer drugs to tumor patients sooner. However, there is no guideline regarding non-clinical safety studies on the development of anticancer drugs required for the first in human clinical trials and for the approval applications in Japan. Then, the Ministry of Health, Labour and Welfare (MHLW) established the collaboration group including regulatory, academic and industrial scientists to prepare the guideline on the non-clinical safety evaluation of anticancer drugs in 2004. As a guide for basic concept of non-clinical safety studies on anticancer drugs, the "Points to Consider" document was prepared by this group in 2007.

Cite

CITATION STYLE

APA

Nakae, D., Onodera, H., Fueki, O., Urano, T., Komiyama, N., Sagami, F., … Inoue, T. (2008). Points to consider on the non-clinical safety evaluation of anticancer drugs. Journal of Toxicological Sciences. Japanese Society of Toxicology. https://doi.org/10.2131/jts.33.123

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free